Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Literature
1.
Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis. 2011;31:449–57.CrossRefPubMed
2.
Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002;42:18–26.CrossRefPubMed
3.
Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost. 2009;101:852–9.PubMed
4.
Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol. 2004;77:363–5.CrossRefPubMed
5.
Perdekamp MT, Rubenstein DA, Jesty J, Hultin MB. Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assays. Blood Coagul Fibrinolysis. 2006;17:593–7.CrossRefPubMed
6.
Lebrun A, Leroy-Matheron C, Arlet J-B, Bartolucci P, Michel M. Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol. 2008;83:163–4.CrossRefPubMed
7.
Metadata
Title
Complete response of acquired FV inhibitor to rituximab
Authors
Edmond S. K. Ma
Raymond H. S. Liang
Kent-Man Chu
George K. K. Lau
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1742-z

Other articles of this Issue 4/2015

International Journal of Hematology 4/2015 Go to the issue

Progress in Hematology

Regulation of myelopoiesis by the transcription factor IRF8

Original Article

A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies

Case Report

Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS)

Original Article

Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT

Original Article

Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders

Original Article

The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits